Pfizer Inc. believes it will be well positioned to execute on the long-term commercial opportunity in COVID-19 when the market transitions from government contracting to a traditional open market, CEO Albert Bourla said during the company's first quarter sales and earnings call on 28 July. But despite Pfizer’s bullish long-term outlook for its COVID-19 franchise, some investors are uncertain the company can deliver on that goal as the public health crisis evolves.
"Hope is not science, and science is telling us that COVID-19 likely will remain a major global health care concern for years to come," Bourla said